|The PKHD1L1 pkhd1l1 (Catalog #MBS644922) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The PKHD1L1 (Fibrocystin-L, Polycystic Kidney and Hepatic Disease 1-like Protein 1, PKHD1-like Protein 1, DKFZp586C1021) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s PKHD1L1 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Western Blot (WB).
Suitable for use in ELISA and Western Blot. Researchers should empirically determine the suitability of the PKHD1L1 pkhd1l1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The PKHD1L1 pkhd1l1 product has the following accession number(s) (GI #62203455) (NCBI Accession #AAH93096.1) (Uniprot Accession #Q86WI1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful. The amino acid sequence is listed below:
KATDSDGNCV SVGITALTLR AILKDSNNNQ VNGLSGNTTI PFSSCWANYT DLTPLRTGKN YKIEFILDNV VGVESRTFSL LA.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Immunogen: Partial recombinant corresponding to aa4105-4187 from human PKHD1L1 (NP_803875) with GST tag. MW of the GST tag alone is 26kD. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PKHD1L1 are readily searchable from our website. Different antibodies against the same target such as PKHD1L1 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.